OBESITY THERAPY AND HEART RATE VARIABILITY

• US 20120172783A1
• Filed: 12/29/2010
• Published: 07/05/2012
• Est. Priority Date: 12/29/2010
• Status: Abandoned Application

• Current Assignee: Ethicon Endo-Surgery, Inc. (Johnson & Johnson)
• Original Assignee: Ethicon Endo-Surgery, Inc. (Johnson & Johnson)
• Inventors: Harris, Jason L., Voegele, Aaron C., Baynham, Tamara C., Ortiz, Mark S., Anton, Edward C. III, Filardo, Thomas W.
• Application Number:
  US12/980,710
• Publication Number:
  US 20120172783A1
• Time in Patent Office: Days
• US Class Current: 604/20
• CPC Class Codes: A61F 5/0013 Implantable devices or invasive measures
• CPC Class Codes: A61F 5/0026 Anti-eating devices using electrical stimulation

Abstract

Methods and devices are provided for delivering obesity therapy to a patient. In general, the methods and devices allow for onset of a patient eating solid food, e.g., the patient beginning a meal, to trigger delivery of an obesity therapy to a patient. The obesity therapy can be delivered to the patient for a limited period of time such that the patient stops receiving the obesity therapy prior to a second onset of the patient eating solid food, e.g., the patient beginning a second meal, which can trigger a second delivery of the obesity therapy to the patient for a limited period of time.

Claims

1. A medical system, comprising:

a sensor configured to be positioned in contact with a tissue of a patient to gather data, the gathered data including at least one of pH levels in a stomach of the patient and a heart rate of the patient;

a processor configured to be in communication with the sensor and to analyze the sensed data to determine onset of solid food ingestion by the patient; and

a delivery device configured to be implanted within the patient and to be in communication with the processor, the delivery device being defaulted to a dormant mode in which the delivery device does not deliver an obesity therapy to the patient, and the delivery device being configured to change from the dormant mode to a delivery mode, in which the delivery device delivers the obesity therapy to the patient, in response to the processor determining onset of the solid food ingestion,

wherein the obesity therapy comprises electrical stimulation of the patient and administration of a chemical to the patient.

2. The system of claim 1, wherein the sensor is configured to gather data including the pH levels in a stomach of the patient and the heart rate of the patient, and the processor is configured to analyze the pH levels and the heart rate to determine onset of the solid food ingestion.

3. The system of claim 1, wherein the sensor is configured to gather data including only one the pH levels in a stomach of the patient and the heart rate of the patient, and the processor is configured to analyze only the one of the pH levels and the heart rate to determine onset of the solid food ingestion.

4. The system of claim 1, wherein the processor is configured to analyze the sensed heart rate data by analyzing a power spectral density in low frequency and high frequency bands to determine onset of the solid food ingestion.

5. The system of claim 1, wherein the chemical comprises a nutrient configured to provoke a release of one or more hormones from L cells of the patient.

6. The system of claim 1, wherein the delivery device is configured to change from the delivery mode to the dormant mode upon occurrence of a predetermined trigger event, and is configured to repeatedly change between the delivery and dormant modes based on the processor determining onsets of solid food ingestion and based on occurrences of the predetermined trigger event.

7. The system of claim 6, wherein the predetermined trigger event comprises passage of a predetermined amount of time during which the delivery device is in the delivery mode.

8. The system of claim 6, wherein the delivery device comprises a reservoir, the reservoir being configured to contain a supply of the chemical and to release a partial portion of the chemical supply each time the delivery device is in the delivery mode.

9. The system of claim 1, wherein the delivery device is configured to be implanted in an intestine of the patient, to electrically stimulate the intestine when the delivery device is in the delivery mode, and to administer the chemical in the intestine when the delivery device is in the delivery mode.

10. The system of claim 1, wherein the processor is configured to be implanted within the patient.

11. The system of claim 1, wherein the processor is configured to be transcutaneously positioned.

12. The system of claim 1, wherein the sensor is configured to be implanted within the patient.

13. The system of claim 1, wherein the sensor is configured to be transcutaneously positioned such that the sensor is in direct contact with an exterior skin surface of the patient.

14. A medical method, comprising:

determining an onset of solid food ingestion by a patient by detecting a change in heart rate of the patient and a change in a pH level in a stomach of the patient; and

in response to the detection of the change in heart rate and the change in the pH level, starting delivery of an obesity therapy to the patient, wherein the obesity therapy includes electrical stimulation of a tissue of the patient and administration of a chemical to the patient.

15. The method of claim 14, wherein the chemical comprises a nutrient.

16. The method of claim 14, further comprising:

after starting delivery of the obesity therapy, stopping delivery of the obesity therapy when a predetermined trigger event occurs; and

repeating the starting and the stopping such that the obesity therapy is intermittently delivered to the patient.

17. The method of claim 14, wherein the electrical stimulation is delivered to the patient at a first location, and the chemical is administered to a patient at a second, substantially different location.

18. The method of claim 17, wherein the first location comprises an intestine of the patient, and the second location comprises a stomach of the patient.

19. A computer readable medium having a program stored thereon, wherein the program causes a computer to perform the steps of:

determining an onset of solid food ingestion by a patient by detecting a change in heart rate of the patient and a change in a pH level in a stomach of the patient; and

in response to the detection of the change in heart rate and the change in the pH level, starting delivery of an obesity therapy to the patient, wherein the obesity therapy includes electrical stimulation of a tissue of the patient and administration of a chemical to the patient.